

Study: ARX-945-RA-II

Protocol: CT-204-II

Sponsor: Ardentis Biotherapeutics Ltd.

Site No.: 104 **Subject ID:** 1

Document: Disease Activity / Efficacy Assessment (Repeating)

Visit	Tender	Swollen	CRP (mg/L)	DAS28 (CRP)	HAQ- DI	Pt VAS	Phy VAS	ACR20	ACR50
Baseline	18	14	12.6	5.9	1.5	65	60	N	N
Week 2	15	12	11.3	5.5	1.4	60	58	N	N
Week 4	11	9	9.4	4.9	1.2	55	50	Y	N
Week 8	7	6	7.1	4.2	1.0	45	42	Y	Y
Week 10	6	5	6.8	4.0	0.9	40	38	Y	Y